Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

aTYR PHARMA (ATYR) Accumulated Depreciation & Amortization (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 6.3% year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Dec 2025, up 6.3%, and an annual FY2025 reading of $4.8 million, up 6.3% over the prior year.
  • Accumulated Depreciation & Amortization was $4.8 million for Q4 2025 at aTYR PHARMA, up from $4.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.4 million in Q4 2022 and bottomed at $4.5 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $5.3 million, with a median of $4.8 million recorded in 2025.
  • The sharpest move saw Accumulated Depreciation & Amortization dropped 27.27% in 2023, then increased 6.3% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $6.2 million in 2021, then grew by 3.2% to $6.4 million in 2022, then decreased by 27.27% to $4.6 million in 2023, then dropped by 1.71% to $4.5 million in 2024, then rose by 6.3% to $4.8 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ATYR at $4.8 million in Q4 2025, $4.5 million in Q4 2024, and $4.6 million in Q4 2023.